1'-(diphenylmethyl)-5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one | 1019767-57-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1'-(diphenylmethyl)-5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one
• 英文别名: (diphenylmethyl)-5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one；1'-benzhydryl-5-methoxyspiro[2H-furo[2,3-c]pyridine-3,3'-indole]-2'-one
• CAS: 1019767-57-7
• 化学式: C₂₈H₂₂N₂O₃
• 分子量: 434.494
• InChiKey: ZHOGUJSKSATCOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1'-(diphenylmethyl)-5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one 在 三乙基硅烷 、 caesium carbonate 、 三氟乙酸 作用下， 反应 9.5h， 生成 5-methoxy-1'-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one
  参考文献：
  名称：

  Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model

  摘要：

  The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNa(V)1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.

  DOI：

  10.1007/s00044-012-0180-1
• 作为产物：
  描述：

  5-溴-2-甲氧基吡啶 在 正丁基锂 、 氯化亚砜 、 叔丁基锂 、 sodium hydride 、 caesium carbonate 、 溶剂黄146 、 三乙胺 、 三氟乙酸 、 锌 作用下， 以 四氢呋喃 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 94.5h， 生成 1'-(diphenylmethyl)-5-methoxyspiro[furo[2,3-c]pyridine-3,3'-indol]-2'(1'H)-one
  参考文献：
  名称：

  Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model

  摘要：

  The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNa(V)1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.

  DOI：

  10.1007/s00044-012-0180-1

文献信息

• SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN
  申请人：Cadieux Jean-Jacques

  公开号：US20110294842A9

  公开（公告）日：2011-12-01

  This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X, R 1 , R 2a , R 2b , R 2c , R 2d and R 3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及使用式（I）的螺环氧吲哚化合物的方法：其中j、k、m、Q、X、R1、R2a、R2b、R2c、R2d和R3如此定义，作为立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、N-氧化物、溶剂合物或前药，用于治疗和/或预防钠通道介导的疾病或病症，如疼痛。
• WO2008/46049
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN<br/>[FR] DÉRIVÉS DE SPIRO (FURO [3, 2-C] PYRIDINE-3-3 ' -INDOL) -2' (1'H)-ONE ET COMPOSÉS CONNEXES UTILISABLES POUR TRAITER DES MALADIES DONT LA MÉDIATION EST ASSURÉE PAR LES CANAUX SODIQUES, COMME LA DOULEUR
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2008046049A1

  公开（公告）日：2008-04-17

  [EN] This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein j, k, m, Q, X,, R¹, R^2a, R^2b, R^2c, R^2d and R³ are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, N-oxide, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
  [FR] La présente invention concerne des procédés d'utilisation de composés de spiro-oxindole de formule (I) : dans laquelle j, k, m, Q, X,, R¹, R^2a, R^2b, R^2c, R^2d et R³ sont tels que définis ici, en tant que stéréoisomère, énantiomère, tautomère de ceux-ci ou que mélanges de ceux-ci; ou un sel, un N-oxyde, un solvate ou un promédicament pharmaceutiquement acceptable de ceux-ci, pour le traitement et/ou la prévention de maladies ou d'affections induites par les canaux sodiques telles que la douleur.
• Tetracyclic spirooxindole blockers of hNaV1.7: activity in vitro and in CFA-induced inflammatory pain model
  作者：Sultan Chowdhury、Shifeng Liu、Jay A. Cadieux、Tom Hsieh、Mikhail Chafeev、Shaoyi Sun、Qi Jia、Jianyu Sun、Mark Wood、Jonathan Langille、Serguei Sviridov、Jianmin Fu、Zaihui Zhang、Ray Chui、Audrey Wang、Xing Cheng、Jing Zhong、Sazzad Hossain、Kuldip Khakh、Ivana Rajlic、Henry Verschoof、Rainbow Kwan、Wendy Young

  DOI：10.1007/s00044-012-0180-1

  日期：2013.4

  The structure-activity relationship of a new series of tetracyclic spirooxindoles led to the discovery of compound 25a, a potent hNa(V)1.7 blocker with improved ADME properties and in vivo efficacy in the CFA-induced inflammatory pain model.